On Wednesday, clinical trial data for Eli Lilly‘s experimental weight-loss drug, orforglipron, provided positive signals for its approval process. However, the company reiterated that it is still too early to determine whether the drug will be included in the new accelerated review procedure in the United States. As a result, Eli Lilly’s stock price rose by approximately 0.5% that day. The oral drug is designed to mimic the GLP-1 hormone pathway targeted by its already marketed products Mounjaro and Zepbound (with the active ingredient tirzepatide), suppressing appetite to achieve weight loss and blood sugar reduction.
Eli Lilly has been working to expand its lead over its Danish competitor Novo Nordisk in the rapidly growing GLP-1 drug market. In a head-to-head trial involving adults with type 2 diabetes, orforglipron demonstrated superior efficacy in lowering blood sugar and reducing weight compared to Novo Nordisk’s oral drug Rybelsus.
Daniel Barasa, a portfolio manager at Gabelli Funds, noted that these data reinforce market confidence in Eli Lilly’s ability to maintain its leadership in the GLP-1 field, not only due to its superior efficacy but also because of the greater convenience of its oral administration. Complete data from another late-stage trial showed that the drug helped overweight adults lose approximately 12% of their body weight, with a safety profile similar to that of injectable formulations. Evan Seigerman, an analyst at BMO Capital Markets, also stated that the new data further solidify optimistic expectations for orforglipron’s competitiveness.
As the world’s most valuable pharmaceutical company by market capitalization, Eli Lilly is actively expanding its production capacity in the United States and globally to meet the sharply rising demand for GLP-1 drugs and to compete with Novo Nordisk in advancing the launch of oral weight-loss medications. Novo Nordisk expects U.S. regulators to make a review decision on its oral weight-loss candidate later this year.
Although several Wall Street analysts believe orforglipron may qualify for the FDA’s newly launched priority review mechanism, designed to accelerate the approval of drugs addressing significant public health needs, Eli Lilly executives remain cautious. Patrick Johnson, President of Lilly International, stated that the company currently has limited understanding of the so-called “National Priority Voucher” and does not plan to submit a related application for now.
Additionally, Eli Lilly’s diabetes drug Mounjaro showed promising results in a study involving adolescents aged 10 to 17, significantly reducing blood sugar levels by approximately 2% and body weight by over 10%. The company has submitted the study data to global regulators, seeking to expand the drug’s indication to adolescent populations. If approved, Mounjaro would become the first GLP-1 drug specifically approved for treating type 2 diabetes in adolescents.
